CTI BioPharma Corp.
CTIC
Updated: 24/09/2026, 18:07:06
No historical data available
CTI BioPharma Corp. is a biopharmaceutical company dedicated to the discovery, advancement, and commercialization of innovative, targeted treatments for blood cancers within the United States. Its key product is VONJO (pacritinib), an oral kinase inhibitor currently under investigation, specifically designed to target JAK2, FLT3, IRAK1, and CSF1R for the management of adult patients with myelofibrosis. The company holds licensing and collaboration agreements with Teva Pharmaceutical Industries Ltd., SBIO Pte Ltd., and Baxalta. Established in 1991 and based in Seattle, Washington, CTI BioPharma Corp. was previously known as Cell Therapeutics, Inc., adopting its current name in May 2014.
No summaries found.
- Share price
- $9.10
- Market cap
- $1.20B
- Exchange
- NASDAQ
- Currency
- USD
- CEO
- Adam R. Craig
- Employees
- 127
- IPO date
- 21/03/1997
- Beta
- 0.830633
- Last dividend
- $0.00
- Day range
- $9.09 – $9.10
- 52-week range
- $4.01 – $9.10
- 1-day performance
- 0.06%
- 1-year performance
- 126.81%
- Current drawdown (1Y)
- -0.05%
- CIK
- 0000891293
- CUSIP
- 12648L601
- ISIN
- US12648L6011
- Created
- 07/12/2025, 03:29:15
- Last update
- 24/09/2026, 18:07:06
Track CTI BioPharma Corp. with an AI analyst
See which prediction-market events move CTIC, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
No news found for this symbol.